UPDATE 1-Eleven Bio's eye drug fails another late-stage study
January 15, 2016 at 17:07 PM EST
Jan 15 (Reuters) - Eleven Biotherapeutics Inc said its lead eye drug failed in a late-stage trial in treating patients with severe allergic conjunctivitis, sending its shares down 36 percent in after-market trading.
